This study will use light scattering spectroscopy (LSS) to analyze brain tissue removed from
patients during brain surgery to determine if this new technology can be used to
differentiate between normal and cancerous cells. LSS focuses light on cells or tissues,
and the way that light is reflected back from the tissues provides information about the
size of cells and the density of the cell nuclei (the part of the cell that contains the
Patients between 18 and 75 years of age with a known or suspected brain tumor and patients
with temporal lobe epilepsy that does not respond to medication may be eligible for this
study. (Examination of tissue from patients with epilepsy will allow comparison of tumor
and non-tumor brain cells.) All patients must require surgery to treat their condition.
Participants will be admitted to the Clinical Center for 3 to 10 days for physical and
neurological examinations, blood and urine tests, and other tests needed to prepare for
surgery. They will then undergo surgery. A small amount of tissue removed during surgery
for pathological review will be collected for use in this study.
Half of the tissue will be examined using LSS to help determine the size of the cell and its
nucleus. Studies will be done to measure how many of the cells are actively dividing and
which proteins are expressed more often in tumor cells compared with normal cells. This
information may shed light on how tumor cells are different from normal cells.
Participants may be contacted for up to 3 years to follow their health status.
Optical spectroscopy for detection of brain tumors and tumor margins has been shown to be of
use in distinguishing gliomas and metastatic tumor cells from surrounding white matter.
Optical spectroscopy has the potential to provide immediate and accurate diagnostic
information about the nature and quantity of neoplastic cells, in a minimally-or
non-invasive fashion. We propose to use a new method of optical spectroscopy, polarized
light-scattering spectroscopy (LSS), which permits discrimination of malignant cancer cells
from normal brain cells by virtue of alterations in the cytoplasmic and nuclear ratios of
Patients suspected of having, or with prior biopsy proof of, a WHO grade II-IV central
nervous system (CNS) glial tumor(s); those with metastatic brain tumor; or patients with
medically-refractory temporal lobe epilepsy with a presumed hippocampal source of seizures,
who are seen in the Surgical Neurology Branch, NINDS, will be considered for entry into this
study. Tissue samples of tumor or normal lateral temporal neocortex resected as part of
standard care will be collected at surgery and utilized for research.
1. Radiographic evidence of primary glial neoplasm of the CNS (WHO grade II-IV) or any
patient with a known primary neoplasm of the CNS; patients with a known or with
radiographic evidence of resectable metastatic brain tumor(s); or patients with
temporal lobe epilepsy (TLE) in whom resective surgery, which will include the
lateral termporal neocortex, is indicated.
2. Informed consent from patients age 18 or older.
3. No racial or ethnic group or gender is excluded.
4. Pregnant women who require brain surgery may participate in this study.
1. Inability to provide informed consent prior to surgery.
2. Medical conditions that cannot be corrected prior to surgery that would be standard
contraindications for neurosurgery.